Dreyling, A. (2009) “Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas”, Hematology Meeting Reports (formerly Haematologica Reports), 2(5). doi: 10.4081/hmr.v2i5.749.